| Outcome Measures: |
Primary: serum Alanine Transaminase (ALT) levels response, defined as ALT value within reference range of <35 IU/L for women and <40 IU/L for men, Week 24|liver fat response, defined as a reduction of ≥6% at week 24 compared to screening by the MRI-Proton Density Fat Fraction (PDFF), Week 24|Percentage of Participants with Adverse Events, 24 weeks | Secondary: percent change from baseline in ALT, Baseline, Week 24|percent change from baseline in ALT, Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24 (or early withdrawal)|percent change from baseline in Aspartate Aminotransferase (AST), Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24 (or early withdrawal)|change from baseline in AST, Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24 (or early withdrawal)|change from baseline in ALT, Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24 (or early withdrawal)|Change from baseline in glycosylated hemoglobin ((HbA1c), Baseline, Weeks 4, 12, and 24 (or early withdrawal)|Change from baseline in liver fibrosis measured using transient elastography (with Fibroscan), Baseline, Week 24 (or early withdrawal)
|
